{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T17:03:15Z","timestamp":1795194195514,"version":"4.10.3"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>\n                      Metabolic-associated fatty liver disease (MAFLD) is a global health concern. Observational evidence has suggested a possible relationship between\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      infection and MAFLD severity; however, severity-focused data remain inconsistent and methodologically heterogeneous.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We searched the international databases PubMed, Embase and Web of Science and the Chinese databases China National Knowledge Infrastructure, Chinese Scientific Journal Database (VIP) and Wanfang between January 2015 and December 2024. Observational studies reporting\n                      <jats:italic>H. pylori<\/jats:italic>\n                      status and MAFLD\/non-alcoholic fatty liver disease (NAFLD) severity were included. Studies using NAFLD criteria were considered clinically comparable with MAFLD because they were conducted before the broad adoption of the MAFLD terminology and enrolled fatty liver disease populations defined by hepatic steatosis with metabolic features. Pooled odds ratios (ORs) were calculated using random-effects models with restricted maximum likelihood estimation and Hartung\u2013Knapp adjustment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seven studies, comprising 11,168 participants (4,980\n                      <jats:italic>H. pylori<\/jats:italic>\n                      -positive; 6,188\n                      <jats:italic>H. pylori<\/jats:italic>\n                      -negative), were included. The overall random-effects analysis did not demonstrate a statistically significant association between\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection and MAFLD severity (pooled OR 1.47, 95% confidence interval [CI]: 0.83\u20132.59,\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.148\n                      <jats:italic>; \u03c4<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f0.1325), with substantial heterogeneity (\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f79.0%). In the non-invasive assessment subgroup, the pooled estimate was OR\u202f=\u202f1.22 (95% CI: 0.95\u20131.57). The two biopsy-based studies showed high but highly imprecise individual estimates and were not interpreted as evidence of a stronger association. Geographic analysis showed an association only in Chinese populations (OR\u202f=\u202f1.31, 95% CI: 1.15\u20131.49,\n                      <jats:italic>I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      =\u202f0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Current evidence does not demonstrate a statistically significant overall association between\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection and MAFLD severity. A modest association was observed in Chinese studies, although biopsy-based evidence remains too imprecise for inference. Large-scale prospective studies with standardized assessment of active\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection and MAFLD severity are needed before causal or therapeutic conclusions can be drawn.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1821076","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:44:40Z","timestamp":1781671480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Helicobacter pylori and metabolic-associated fatty liver disease severity: a meta-analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Lingyun","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuexia","family":"Zhang","sequence":"additional","affiliation":[{"name":"Health Management Center, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Beijing Jishuitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41575-020-0316-6","article-title":"From NAFLD to MAFLD: when pathophysiology succeeds","volume":"17","author":"Tilg","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"International consensus panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"154170","DOI":"10.1016\/j.metabol.2020.154170","article-title":"Complications, morbidity and mortality of nonalcoholic fatty liver disease","author":"Mantovani","year":"2020","journal-title":"Metabolism"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/hel.12256","article-title":"Extragastric diseases and Helicobacter pylori","volume":"20","author":"Franceschi","year":"2015","journal-title":"Helicobacter"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0128671","DOI":"10.1371\/journal.pone.0128671","article-title":"Helicobacter pylori infection increases insulin resistance and metabolic syndrome in residents younger than 50 years old: a community-based study","volume":"10","author":"Chen","year":"2015","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1523-5378.2011.00822.x","article-title":"The association between Helicobacter pylori infection and insulin resistance: a systematic review","volume":"16","author":"Polyzos","year":"2011","journal-title":"Helicobacter"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e12576","DOI":"10.1111\/hel.12576","article-title":"Association between Helicobacter pylori infection and nonalcoholic fatty liver disease: a systematic review and meta-analysis of observational studies","volume":"24","author":"Zhou","year":"2019","journal-title":"Helicobacter"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1111\/liv.15925","article-title":"Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: an updated meta-analysis","volume":"44","author":"Mantovani","year":"2024","journal-title":"Liver Int"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1410543","DOI":"10.3389\/fnut.2024.1410543","article-title":"Bidirectional relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: insights from a comprehensive meta-analysis","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Nutr"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e26706","DOI":"10.1097\/MD.0000000000026706","article-title":"Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: what should we expect from a meta-analysis?","volume":"100","author":"Wei","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref17","volume-title":"The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses","author":"Wells","year":"2013"},{"key":"ref18","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.5","author":"Higgins","year":"2024"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1007\/s00535-015-1039-2","article-title":"Helicobacter pylori infection might have a potential role in hepatocyte ballooning in nonalcoholic fatty liver disease","volume":"50","author":"Sumida","year":"2015","journal-title":"J Gastroenterol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3390\/jcm9040933","article-title":"Active Helicobacter pylori infection is independently associated with nonalcoholic steatohepatitis in morbidly obese patients","volume":"9","author":"Doulberis","year":"2020","journal-title":"J Clin Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/MEG.0000000000001601","article-title":"Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome","volume":"32","author":"Chen","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e0260994","DOI":"10.1371\/journal.pone.0260994","article-title":"The association between Helicobacter pylori with nonalcoholic fatty liver disease assessed by controlled attenuation parameter and other metabolic factors","volume":"16","author":"Han","year":"2021","journal-title":"PLoS One"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.15537\/smj.2021.42.7.20210040","article-title":"Association between nonalcoholic fatty liver disease and Helicobacter pylori infection in Dali City, China","volume":"42","author":"Yan","year":"2021","journal-title":"Saudi Med J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"9797841","DOI":"10.1155\/2020\/9797841","article-title":"Nonalcoholic fatty liver disease is associated with Helicobacter pylori infection in north urban Chinese: a retrospective study","volume":"2020","author":"Xu","year":"2020","journal-title":"Gastroenterol Res Pract"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"764472","DOI":"10.3389\/fmed.2021.764472","article-title":"Association between Helicobacter pylori infection and non-alcoholic fatty liver disease, hepatic adipose deposition and stiffness in Southwest China","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrgastro.2013.243","article-title":"Clinical effects of Helicobacter pylori outside the stomach","volume":"11","author":"Franceschi","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"CGast.S13760","DOI":"10.4137\/CGast.S13760","article-title":"Virulence factors of Helicobacter pylori: a review","volume":"7","author":"Roesler","year":"2014","journal-title":"Clin Med Insights Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1291501","DOI":"10.3389\/fmed.2024.1291501","article-title":"Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies","volume":"11","author":"Habibullah","year":"2024","journal-title":"Front Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1590\/S0004-28032014000300017","article-title":"Effect of Helicobacter pylori eradication on hepatic steatosis, NAFLD fibrosis score and HSENSI in patients with nonalcoholic steatohepatitis: a MR imaging-based pilot open-label study","volume":"51","author":"Polyzos","year":"2014","journal-title":"Arq Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e14679","DOI":"10.5812\/hepatmon.14679","article-title":"The effect of Helicobacter pylori eradication on liver fat content in subjects with non-alcoholic fatty liver disease: a randomized open-label clinical trial","volume":"13","author":"Jamali","year":"2013","journal-title":"Hepat Mon"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s43066-019-0001-z","article-title":"Investigating effect of Helicobacter pylori treatment on improvement of non-alcoholic fatty liver parameters: a randomized trial","volume":"9","author":"Kazemifar","year":"2019","journal-title":"Egypt Liver J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/gastro\/goz058","article-title":"Effect of Helicobacter pylori-eradication therapy on hepatic steatosis in patients with non-alcoholic fatty liver disease: a randomized-controlled pilot study","volume":"8","author":"Maharshi","year":"2020","journal-title":"Gastroenterol Rep"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"19530","DOI":"10.1038\/s41598-022-23746-0","article-title":"Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial","volume":"12","author":"Yu","year":"2022","journal-title":"Sci Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1821076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:44:54Z","timestamp":1781671494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1821076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":34,"alternative-id":["10.3389\/fmed.2026.1821076"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1821076","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1821076"}}